[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2016000278A - Nuevos compuestos macrocíclicos - Google Patents

Nuevos compuestos macrocíclicos

Info

Publication number
DOP2016000278A
DOP2016000278A DO2016000278A DO2016000278A DOP2016000278A DO P2016000278 A DOP2016000278 A DO P2016000278A DO 2016000278 A DO2016000278 A DO 2016000278A DO 2016000278 A DO2016000278 A DO 2016000278A DO P2016000278 A DOP2016000278 A DO P2016000278A
Authority
DO
Dominican Republic
Prior art keywords
macrocyclic compounds
new macrocyclic
compounds
general formula
new
Prior art date
Application number
DO2016000278A
Other languages
English (en)
Inventor
Gang Chen
Philip Lienau
Arne Scholz
Ulf Bömer
Christian Stegmann
Ulrich Lücking
Pierre Wasnaire
Gerhard Simeister
Kunzeng Zheng
Ping Gao
Jiajun Xi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2016000278A publication Critical patent/DOP2016000278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevos compuestos macrocíclicos de la fórmula general (I) como se los describe y se los define en la memoria descriptiva. Métodos para prepararlos. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermedios útiles para preparar los compuestos de la fórmula general (I).
DO2016000278A 2014-04-11 2016-10-11 Nuevos compuestos macrocíclicos DOP2016000278A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014000392 2014-04-11

Publications (1)

Publication Number Publication Date
DOP2016000278A true DOP2016000278A (es) 2016-11-15

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000278A DOP2016000278A (es) 2014-04-11 2016-10-11 Nuevos compuestos macrocíclicos

Country Status (28)

Country Link
US (1) US9963464B2 (es)
EP (1) EP3129387B1 (es)
JP (1) JP6605493B2 (es)
KR (1) KR102383938B1 (es)
CN (1) CN106459084B (es)
AP (1) AP2016009483A0 (es)
AR (1) AR099999A1 (es)
AU (1) AU2015243585B2 (es)
BR (1) BR112016023554B1 (es)
CA (1) CA2945237C (es)
CL (1) CL2016002577A1 (es)
CR (1) CR20160471A (es)
CU (1) CU24399B1 (es)
DO (1) DOP2016000278A (es)
EA (1) EA032541B1 (es)
ES (1) ES2743799T3 (es)
IL (1) IL247966B (es)
MX (1) MX2016013362A (es)
PE (1) PE20161379A1 (es)
PH (1) PH12016501968A1 (es)
SG (1) SG11201608430RA (es)
SV (1) SV2016005301A (es)
TN (1) TN2016000435A1 (es)
TW (1) TW201623312A (es)
UA (1) UA119349C2 (es)
UY (1) UY36072A (es)
WO (1) WO2015155197A1 (es)
ZA (1) ZA201607765B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
EP3359544B1 (en) * 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
MA44721B1 (fr) * 2016-04-22 2020-05-29 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
EP3528812B1 (en) * 2016-10-20 2020-12-30 Pfizer Inc Palbociclib for treating pah
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
EP4412655A1 (en) 2021-10-04 2024-08-14 Vincerx Pharma GmbH Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059110A1 (en) 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2006064251A1 (en) 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
MX2009006536A (es) 2006-12-22 2009-06-26 Novartis Ag Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
CN101568530A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
MX2012010966A (es) 2010-03-22 2013-01-29 Lead Discovery Center Gmbh Derivados de triazina disustituidos farmaceuticamente activos.
WO2012117059A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted pyridine derivatives
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CN103917527B (zh) * 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
WO2014060376A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
WO2014076028A1 (en) 2012-11-15 2014-05-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
PT2928878T (pt) 2012-11-15 2017-02-08 Bayer Pharma AG Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina contendo um grupo sulfoximina
JP6371385B2 (ja) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

Also Published As

Publication number Publication date
CN106459084B (zh) 2019-04-19
AR099999A1 (es) 2016-08-31
PH12016501968A1 (en) 2016-12-19
AU2015243585B2 (en) 2019-08-01
MX2016013362A (es) 2017-02-09
EP3129387B1 (en) 2019-06-26
PE20161379A1 (es) 2017-01-15
AP2016009483A0 (en) 2016-10-31
SV2016005301A (es) 2018-03-12
EP3129387A1 (en) 2017-02-15
BR112016023554A2 (pt) 2017-08-15
TW201623312A (zh) 2016-07-01
CL2016002577A1 (es) 2017-04-07
JP2017510598A (ja) 2017-04-13
CU24399B1 (es) 2019-04-04
IL247966B (en) 2021-02-28
WO2015155197A1 (en) 2015-10-15
CU20160152A7 (es) 2017-04-05
ES2743799T3 (es) 2020-02-20
ZA201607765B (en) 2022-09-28
JP6605493B2 (ja) 2019-11-13
CN106459084A (zh) 2017-02-22
SG11201608430RA (en) 2016-11-29
KR20160136449A (ko) 2016-11-29
CR20160471A (es) 2016-12-21
AU2015243585A1 (en) 2016-10-13
TN2016000435A1 (en) 2018-04-04
CA2945237A1 (en) 2015-10-15
US20170029439A1 (en) 2017-02-02
EA032541B1 (ru) 2019-06-28
BR112016023554B1 (pt) 2023-03-14
UY36072A (es) 2015-11-30
UA119349C2 (uk) 2019-06-10
CA2945237C (en) 2022-09-06
IL247966A0 (en) 2016-11-30
EA201692034A1 (ru) 2017-04-28
KR102383938B1 (ko) 2022-04-08
US9963464B2 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
DOP2016000278A (es) Nuevos compuestos macrocíclicos
CR20150256A (es) Derivados de 5-fluoro-n-(piridin-2- amina que contienen un grupo sulfoximina
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CR20130620A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
EA201790630A1 (ru) Способы получения рибозидов
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
UY35139A (es) 4- (orto) -fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
UY36938A (es) Nuevos compuestos macrocíclicos modificados
DOP2015000117A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CR20150641U (es) Composiciones farmacéuticas
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas
CR20150060A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.